{"id":3572,"date":"2017-12-12T17:10:05","date_gmt":"2017-12-12T22:10:05","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3572"},"modified":"2017-12-12T17:12:03","modified_gmt":"2017-12-12T22:12:03","slug":"secondaries-announced-12-12-17","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/secondaries-announced-12-12-17\/","title":{"rendered":"Secondaries announced 12.12.17"},"content":{"rendered":"

IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis.<\/strong><\/h4>\n

If having\u00a0real-time alerts for secondary offerings<\/strong><\/a>\u00a0would be an advantage to you,\u00a0inquire about a subscription today!<\/a><\/p>\n

Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or opening trade) time period.<\/p>\n

Company: Aker Biosciences, Inc.
\nSymbol: AKER
\nPrice: Last Trade $0.42
\nTrade Date: 12\/15
\nShares: 13.6 million
\nUnderwriter(s): Joseph Gunnar & Co.
\nDescription: Akers Bio develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

\"Screen<\/a><\/p>\n

Company: Fate Therapeutics, Inc.
\nSymbol: FATE
\nPrice: Last Trade $4.43
\nTrade Date: 12\/13
\nShares: 7.1 million ($30 million cash raise)
\nRe-Offer Range:Subscription Needed<\/a><\/strong>
\nUnderwriter(s): Leerink, Piper Jaffray
\nDescription: Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: Helios and Matheson Analytics Inc.
\nSymbol: HMNY
\nPrice: Last Trade $10.08
\nTrade Date: 12\/13
\nShares: 4.96 million ($50 million cash raise)
\nRe-Offer Range:Subscription Needed<\/a><\/strong>
\nUnderwriter(s): Canaccord Genuity
\nCo-Manager(s): Maxim Group
\nDescription: They are a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening, and consumer-centric technology.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: Subscription Needed<\/a><\/strong>
\nSymbol: PTI
\nPrice: Last Trade $6.14
\nTrade Date: 12\/14
\nShares: 7 million
\nUnderwriter(s): Leerink, RBC Capital
\nCo-Manager(s): H.C. Wainwright
\nDescription: Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: Nordic American Tankers
\nSymbol: NAT
\nPrice: Last Trade $3.67
\nTrade Date: 12\/13
\nShares: 27.3 million ($100 million cash raise)
\nRe-Offer Range:Subscription Needed<\/a><\/strong>
\nUnderwriter(s): Morgan Stanley, Clarksons Platou Securities, DNB Markets, Skandinaviska Enskilda Banken AB, Seaport Global
\nDescription: Nordic American Tankers Limited, incorporated on June 12, 1995, is an international tanker company.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: Intellia Therapeutics – Block
\nSymbol: NTLA
\nPrice: Last Trade $18.30
\nTrade Date: 12\/13
\nShares: 1.523 million
\nRe-Offer Range: Subscription Needed<\/a><\/strong>
\nUnderwriter(s): UBS
\nDescription: They are developing revolutionary genome editing therapies to cure genetic diseases with simple, targeted treatments.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n

Company: Noble Midstream Partners
\nSymbol: NBLX
\nPrice: Last Trade $51.55
\nTrade Date: 12\/13
\nShares: 3.2 million
\nRe-Offer Range:\u00a0Subscription Needed<\/a><\/strong>
\nUnderwriter(s): Citigroup
\nDescription: They are engaged in owning, operating, developing and acquiring a range of domestic midstream infrastructure assets.
\nRating = Subscription Needed<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

IPO BOUTIQUE CLIENTS\u00a0and\u00a0IPO BOUTIQUE SECONDARY ALERTS CLIENTS\u00a0received ALL this information to their inbox on a\u00a0REAL TIME\u00a0basis. If having\u00a0real-time alerts for secondary offerings\u00a0would be an advantage to you,\u00a0inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[35],"tags":[],"class_list":["post-3572","post","type-post","status-publish","format-standard","hentry","category-secondary-offerings"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3572"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3572\/revisions"}],"predecessor-version":[{"id":3575,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3572\/revisions\/3575"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}